Molecular Evidence (rationale) for plasma cell targeted therapy in iMCD patients:


  • "Bortezomib, a selective proteasome inhibitor that preferentially targets plasma cells, has lowered IL-6 levels and induced remission in 4 cases of iMCD" (blood 2014)


Case Reports of anti-plasma cell therapy for iMCD patients:


Bortezomib is "a selective proteasome inhibitor that preferentially targets plasma cells, has lowered IL-6 levels and induced remission in 4 cases of iMCD" (blood 2014"Bortezomib may work in iMCD via direct inhibition of NF-kB" (blood 2014)

  • Please click here to read case reports of iMCD patients receiving Bortezomib.
     

Clinical Trials targeting plasma cells in iMCD: 


No clinical trials targeting plasma cells in iMCD patients have been conducted.